Health Catalyst, Inc. (NASDAQ:HCAT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have received a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $11.79.

Several analysts have recently issued reports on HCAT shares. Royal Bank of Canada boosted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Evercore ISI lifted their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Citigroup boosted their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. lifted their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $6.97 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The business has a 50 day moving average price of $8.13 and a 200 day moving average price of $7.45. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a market capitalization of $424.11 million, a P/E ratio of -5.16 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter last year, the company posted ($0.22) earnings per share. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. Sell-side analysts expect that Health Catalyst will post -0.33 EPS for the current fiscal year.

Insider Activity at Health Catalyst

In related news, insider Linda Llewelyn sold 6,442 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96. Following the transaction, the insider now directly owns 98,702 shares of the company’s stock, valued at approximately $777,771.76. The trade was a 6.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Jason Alger sold 19,599 shares of Health Catalyst stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now directly owns 86,712 shares of the company’s stock, valued at approximately $721,443.84. The trade was a 18.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,551 shares of company stock worth $532,105 in the last quarter. 2.50% of the stock is owned by company insiders.

Institutional Trading of Health Catalyst

Several large investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in shares of Health Catalyst during the 2nd quarter worth approximately $187,000. Nisa Investment Advisors LLC boosted its stake in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after acquiring an additional 5,232 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after buying an additional 1,907 shares during the period. Rhumbline Advisers boosted its stake in Health Catalyst by 9.1% during the 2nd quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock worth $582,000 after acquiring an additional 7,589 shares during the last quarter. Finally, Los Angeles Capital Management LLC increased its position in shares of Health Catalyst by 276.3% in the 2nd quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock valued at $1,365,000 after buying an additional 156,908 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.